Apr 03, 2019 - Top Research Reports for Pfizer, Royal Dutch Shell & Celgene
Apr 03, 2019 - Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
Apr 03, 2019 - Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Apr 03, 2019 - The grandaddy of gene-editing stocks recently provided an encouraging update, but it isn't the only experimental hemophilia therapy out there.
Apr 01, 2019 - Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.
Mar 29, 2019 - Sarepta???s (SRPT) key pipeline candidate leads to statistically significant increase in dystrophin production in ESSENCE study. NDA to be filed mid-2019.
Mar 25, 2019 - Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
Mar 22, 2019 - Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.
Mar 22, 2019 - The index traversed yet another volatile week but still managed to notch up strong gains.
Mar 21, 2019 - The big biotech's pivot from multiple sclerosis to Alzheimer's disease was dealt a decisive blow today.